RNA chemistry

RNA chemistry and therapeutics

RNA-based therapies have made substantial clinical advances. This Review in the November issue describes synthetic methods and chemical modification strategies to enhance their properties.      

  • Siyu Wang
  • Drew Weissman
  • Yizhou Dong
Review Article

Announcements

Advertisement

    • Induced proximity modalities encompass monovalent and bifunctional agents, such as molecular glues and proteolysis-targeting chimeras, that induce an interaction between biomolecules to functionally modulate the target. This Review highlights seminal discoveries in the field, surveys the various modalities and discusses novel approaches to control cellular processes beyond protein degradation.

      • Elizabeth A. King
      • Margot Meyers
      • Daniel K. Nomura
      Review Article
    • Quantitative systems toxicology (QST) models have the potential to increase confidence in the safety assessment of drug candidates and to inform project progression decisions. This article overviews the fundamentals of constructing and using QST models, presents the state-of-the-art for models of cardiovascular, gastrointestinal, hepatic and renal toxicities, and it provides recommendations for their application in drug discovery and development.

      • Christopher E. Goldring
      • Giusy Russomanno
      • Loic Laplanche
      Perspective
    • In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo manufacturing. This Review examines emerging viral and lipid nanoparticle platforms, early clinical proof of concept and potential applications beyond cancer.

      • Adrian Bot
      • Andrew Scharenberg
      • Carl H. June
      Review Article
    • Chronic obstructive pulmonary disease (COPD) is a progressive and severe respiratory disease featuring airway obstruction and recurrent exacerbations, driven by a complex network of inflammatory processes. In their Review, Agusti and co-authors appraise drugs in development for COPD including recently approved antibodies targeting IL-4 and IL-5 signalling. They discuss opportunities to improve the success of future interventions, including considerations to optimize clinical trial design.

      • Alvar Agusti
      • Dave Singh
      • Rosa Faner
      Review Article
    • RNA can be chemically modified by enzymes such as methyltransferases to regulate RNA metabolism, gene expression and other biological processes. This Review mainly focuses on the disease-relevant N6-methyladenosine RNA modification pathway and discusses efforts to therapeutically target N6-methyladenosine writer, eraser and reader proteins.

      • Linda Zhang
      • Jiangbo Wei
      • Chuan He
      Review Article

Advertisement

Nature Careers

Science jobs

Advertisement